RL
78
6
NWS
64
2
HPQ
60
-3
AAP
42
18
FTI
79
-2
SIG
55
5
HUM
43
-6
USB
57
2
NEM
48
2
AON
56
2
QCOM
52
3
KLAC
56
9
MOS
48
2
SYY
56
3
AIZ
82
2
ZTS
56
7
DLTR
44
5
JBHT
63
7
CVS
57
7
DTE
58
2
RL
78
6
NWS
64
2
HPQ
60
-3
AAP
42
18
FTI
79
-2
SIG
55
5
HUM
43
-6
USB
57
2
NEM
48
2
AON
56
2
QCOM
52
3
KLAC
56
9
MOS
48
2
SYY
56
3
AIZ
82
2
ZTS
56
7
DLTR
44
5
JBHT
63
7
CVS
57
7
DTE
58
2
Financhill
Back

Aytu BioPharma 10K Form

Sell
29

AYTU
Aytu BioPharma

Last Price:
1.58
Seasonality Move:
23.23%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AYTU News And Ratings

See the #1 stock for the next 7 days that we like better than AYTU

AYTU Financial Statistics

Sales & Book Value

Annual Sales: $81M
Cash Flow: $-1.33M
Price / Cash Flow: 0
Annual Sales: $4.85
Price / Book: 0.32

Profitability

EPS (TTM): -1.53000
Net Income (TTM): $-6.25M
Gross Margin: $54.59M
Return on Equity: -20.38%
Return on Assets: -4.99%

Aytu BioPharma Earnings Forecast

Key Aytu BioPharma Financial Ratios

  • The Gross Profit Margin over the past 18 years for AYTU is 67.39%.
  • The Selling, General & Administrative Expenses for AYTU have been equal to 61.08% of Gross Profit Margin.
  • The Research & Development expenses have been 3.45% of Revenue.
  • The Interest Expense is -30.24% of Operating Income.
  • The Net Earning history of AYTU is -19.56% of Total Revenues.
  • Per Share Earnings over the last 18 years have been positive in 7 years.

Aytu BioPharma Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: AYTU
CUSIP: 054754
Website: aytubio.com

Debt

Debt-to-Equity Ratio: 0.56
Current Ratio: 0.99
Quick Ratio: 0.71

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AYTU Technical Analysis vs Fundamental Analysis

Sell
29
Aytu BioPharma (AYTU) is a Sell

Is Aytu BioPharma a Buy or a Sell?

  • Aytu BioPharma stock is rated a Sell
    The current Aytu BioPharma [AYTU] share price is $1.57. The Score for AYTU is 29, which is 42% below its historic median score of 50, and infers higher risk than normal.